ET
VRTX icon

Equitable Trust’s Vertex Pharmaceuticals VRTX Stock Holding History

Equitable Trust’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Sell
512
-50
-9% -$22.2K 0.01% 421
2026
Q1 		$251K Buy
562
+66
+13% +$30.8K 0.01% 430
2025
Q4 		$225K Buy
+496
New +$214K 0.01% 421
2025
Q2 		– Sell
-521
Closed -$253K – 472
2025
Q1 		$253K Hold
521
– – 0.01% 428
2024
Q4 		$210K Sell
521
-3
-0.6% -$1.39K 0.01% 458
2024
Q3 		$244K Buy
+524
New +$252K 0.02% 418

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Equitable Trust's VRTX Position: Q2 2026 in Review

Equitable Trust reduced its Vertex Pharmaceuticals (VRTX) stake by 8.9% in Q2 2026, selling an estimated $22.2K and leaving 512 shares worth $254K. The position accounts for 0.01% of the portfolio, ranked #421.

Equitable Trust first reported a position in VRTX in Q3 2024 and has held it in 6 quarters since. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Equitable Trust held 512 shares of Vertex Pharmaceuticals worth $254K as of Q2 2026.
  • Equitable Trust sold 50 Vertex Pharmaceuticals shares in Q2 2026, an estimated $22.2K.
  • Vertex Pharmaceuticals made up 0.01% of Equitable Trust's portfolio in Q2 2026, its #421 holding.
  • Equitable Trust first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Equitable Trust's 13F filing for Q2 2026, filed 23 Jul 2026.